IL164438A0 - Sustaubed release of guaifenesin combination drugs - Google Patents

Sustaubed release of guaifenesin combination drugs

Info

Publication number
IL164438A0
IL164438A0 IL16443803A IL16443803A IL164438A0 IL 164438 A0 IL164438 A0 IL 164438A0 IL 16443803 A IL16443803 A IL 16443803A IL 16443803 A IL16443803 A IL 16443803A IL 164438 A0 IL164438 A0 IL 164438A0
Authority
IL
Israel
Prior art keywords
sustaubed
release
combination drugs
guaifenesin
guaifenesin combination
Prior art date
Application number
IL16443803A
Other languages
English (en)
Original Assignee
Adams Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/121,706 external-priority patent/US6955821B2/en
Priority claimed from US10/406,574 external-priority patent/US7985420B2/en
Priority claimed from US10/406,557 external-priority patent/US7838032B2/en
Application filed by Adams Lab Inc filed Critical Adams Lab Inc
Publication of IL164438A0 publication Critical patent/IL164438A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16443803A 2002-04-15 2003-04-15 Sustaubed release of guaifenesin combination drugs IL164438A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/121,706 US6955821B2 (en) 2000-04-28 2002-04-15 Sustained release formulations of guaifenesin and additional drug ingredients
US10/406,574 US7985420B2 (en) 2000-04-28 2003-04-04 Sustained release of guaifenesin combination drugs
US10/406,557 US7838032B2 (en) 2000-04-28 2003-04-04 Sustained release of guaifenesin

Publications (1)

Publication Number Publication Date
IL164438A0 true IL164438A0 (en) 2005-12-18

Family

ID=29255202

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16443803A IL164438A0 (en) 2002-04-15 2003-04-15 Sustaubed release of guaifenesin combination drugs

Country Status (10)

Country Link
EP (1) EP1503739A4 (es)
JP (1) JP5466346B2 (es)
CN (1) CN1655766B (es)
AU (1) AU2003237807B2 (es)
CA (1) CA2481739C (es)
EA (1) EA007156B1 (es)
IL (1) IL164438A0 (es)
MX (1) MXPA04010225A (es)
WO (1) WO2003088952A1 (es)
ZA (1) ZA200409171B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040682A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
WO2005030132A2 (en) * 2003-09-24 2005-04-07 Combinatorx, Incorporated Therapeutic regimens for administering drug combinations
CA2476101A1 (en) * 2004-08-12 2006-02-12 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride
CN101849921A (zh) * 2004-08-13 2010-10-06 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放片剂
PT3184526T (pt) 2005-12-13 2018-12-19 Incyte Holdings Corp Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus
CN1994285B (zh) * 2006-01-04 2011-03-16 上海医药工业研究院 愈创木酚甘油醚缓释微丸及其制备方法
US20080176955A1 (en) * 2007-01-16 2008-07-24 Victory Pharma, Inc. Combined administration of benzonatate and guaifenesin
CN101658507B (zh) * 2008-08-26 2011-12-07 北京科信必成医药科技发展有限公司 一种愈创木酚甘油醚和伪麻黄碱的复方缓释制剂
US9198904B2 (en) * 2009-02-04 2015-12-01 Astellas Pharma Inc. Pharmaceutical composition for oral administration
TWI766281B (zh) 2010-03-10 2022-06-01 美商英塞特控股公司 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
US9339478B2 (en) 2011-02-04 2016-05-17 Reckitt Benckiser Llc Pharmaceutical formulation
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
CN102755304A (zh) * 2012-08-03 2012-10-31 四川百利药业有限责任公司 一种愈美胶囊的制备方法
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
CN105982860B (zh) * 2015-02-11 2020-04-14 北京科信必成医药科技发展有限公司 愈创甘油醚无水吞服掩味颗粒
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
DE69940557D1 (de) * 1998-12-11 2009-04-23 Nostrum Pharmaceuticals Inc Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
CN100391438C (zh) * 1999-09-14 2008-06-04 史密丝克莱恩比彻姆公司 制备水性包被小球粒的方法
US6372525B1 (en) * 1999-12-20 2002-04-16 Taiwan Semiconductor Manufacturing Company Wafer-level antenna effect detection pattern for VLSI
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US20020022058A1 (en) * 2000-07-08 2002-02-21 Lovercheck Dale R. Unit dose of material in system and method

Also Published As

Publication number Publication date
AU2003237807A1 (en) 2003-11-03
EP1503739A1 (en) 2005-02-09
ZA200409171B (en) 2005-07-27
CN1655766A (zh) 2005-08-17
CN1655766B (zh) 2012-05-30
WO2003088952A1 (en) 2003-10-30
EA200401369A1 (ru) 2005-06-30
JP2005528402A (ja) 2005-09-22
EP1503739A4 (en) 2006-06-21
MXPA04010225A (es) 2005-07-05
JP5466346B2 (ja) 2014-04-09
CA2481739A1 (en) 2003-10-30
EA007156B1 (ru) 2006-08-25
AU2003237807B2 (en) 2008-10-23
CA2481739C (en) 2012-10-02

Similar Documents

Publication Publication Date Title
IL236190A0 (en) Controlled release of anti-infections
HK1084043A1 (en) Derivatives of aryl-quinazoline/aryl-2amino-phenylmethanone which promote the release of parathyroidhormone
PL373914A1 (en) Immediate release dosage forms containing solid drug dispersions
EP1537880A4 (en) PREPARATION FOR PROLONGED RELEASE
IL164438A0 (en) Sustaubed release of guaifenesin combination drugs
HK1085131A1 (en) Solid drug for oral use
TWI319317B (en) Modified release pharmaceutical formulation
EP1895991A4 (en) MODIFIED RELEASE FORMULATIONS OF ANTI-IRRITABLE DRUGS
EP1553925A4 (en) ORAL DOSAGE FORM WITH MODIFIED RELEASE
HK1089697A1 (en) Modafinil modified release pharmaceutical compositions
AU2003260803A8 (en) Sustained release pharmaceutical composition
IL176222A0 (en) Sustained release torsemide dosage forms
EP1411904A4 (en) PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE
EP1564220A4 (en) EXCIPIENT FOR DELAYED RELEASE MEDICINE
PL376840A1 (pl) Kompozycja farmaceutyczna o przedłużonym uwalnianiu
GB0202900D0 (en) Novel formulations of drugs
IL163887A0 (en) Controlled release dosage forms
EP1478353A4 (en) PHARMACEUTICAL COMPOSITION WITH DELAYED RELEASE
EP1484061A4 (en) DRUGS CONTAINING COMPOUNDS OF THE RIBOFLAVIN TYPE
EP1483580A4 (en) BIOLOGICAL MARKER INDICATING THE EFFECTIVENESS OF HUNGER DRUGS
IL176061A0 (en) Nitrooxyderivatives of antihypertensive drugs
EP1501844A4 (en) DISChARIDE FOR DRUG DEVELOPMENT
GB0327742D0 (en) Novel uses of known drugs
HK1087623A1 (en) Combination of antidiabetic drugs
ZA200603030B (en) Modafinil modified release pharmaceutical compositions